Seres Therapeutics (NASDAQ:MCRB) PT Lowered to $6.00 at Chardan Capital

Seres Therapeutics (NASDAQ:MCRB) had its price target lowered by analysts at Chardan Capital from $8.00 to $6.00 in a report issued on Wednesday, Benzinga reports. The firm currently has a “buy” rating on the biotechnology company’s stock. Chardan Capital’s price target would indicate a potential upside of 482.52% from the company’s current price.

Separately, Oppenheimer dropped their target price on shares of Seres Therapeutics from $9.00 to $5.00 and set an “outperform” rating for the company in a research report on Wednesday, March 6th.

Seres Therapeutics Trading Up 37.4 %

Shares of NASDAQ:MCRB opened at $1.03 on Wednesday. The firm has a 50 day moving average of $0.83 and a 200-day moving average of $1.06. The stock has a market capitalization of $155.54 million, a PE ratio of -1.14 and a beta of 2.16. Seres Therapeutics has a 12 month low of $0.54 and a 12 month high of $6.26.

Seres Therapeutics (NASDAQ:MCRB) last issued its earnings results on Tuesday, March 5th. The biotechnology company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.08. The firm had revenue of $0.06 million during the quarter, compared to analyst estimates of $0.50 million. On average, research analysts predict that Seres Therapeutics will post -1.15 EPS for the current fiscal year.

Hedge Funds Weigh In On Seres Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. Hudson Bay Capital Management LP increased its position in Seres Therapeutics by 127.3% during the 3rd quarter. Hudson Bay Capital Management LP now owns 1,999,800 shares of the biotechnology company’s stock worth $4,760,000 after purchasing an additional 1,119,800 shares in the last quarter. Handelsbanken Fonder AB increased its position in Seres Therapeutics by 10.0% during the 4th quarter. Handelsbanken Fonder AB now owns 1,100,000 shares of the biotechnology company’s stock worth $1,540,000 after purchasing an additional 100,000 shares in the last quarter. Rafferty Asset Management LLC increased its position in Seres Therapeutics by 21.1% during the 3rd quarter. Rafferty Asset Management LLC now owns 936,382 shares of the biotechnology company’s stock worth $2,229,000 after purchasing an additional 162,995 shares in the last quarter. Barclays PLC increased its position in Seres Therapeutics by 24.3% during the 3rd quarter. Barclays PLC now owns 461,209 shares of the biotechnology company’s stock worth $1,097,000 after purchasing an additional 90,304 shares in the last quarter. Finally, Pennant Investors LP acquired a new position in Seres Therapeutics during the 4th quarter worth approximately $409,000. 59.34% of the stock is currently owned by institutional investors and hedge funds.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.